Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02278588 · ClinicalTrials.gov registry record
Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.
A clinical trial, sponsored by State University of New York at Buffalo.
- Completed
- Registry status
- 45
- Enrollment target
NCT02278588 is a clinical trial that has completed, run by State University of New York at Buffalo. The registered enrollment target is 45 participants.
The verdict
NCT02278588 has completed, sponsored by State University of New York at Buffalo.
- COMPLETED
- Registry status
- 45 participants
- Enrollment target
Study Summary
In this investigator-initiated study, we will compare changes in brain cognitive biomarkers assessed by diffusion tensor imaging over 2.5 years among 12 patients with Idiopathic Parkinson's disease (IPD) receiving rasagiline, 20 IPD patients not receiving MAO-B inhibitors and 25 age-matched healthy controls. Will also compare the changes in Mini-Mental State Exam (MMSE) and Montreal Cognitive Assessment (MoCA) scores and plasma brain-derived neurotrophic factor (BDNF) with changes in brain cognitive biomarkers in all IPD patients and HC over 2.5 years.
Interventions
- DRUG Rasagiline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2014-11 |
| Est. Completion | 2017-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02278588
The ClinicalTrials.gov registry entry for NCT02278588 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York at Buffalo, which has 243 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rasagiline is the first listed.
NCT02278588 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02278588 about?
NCT02278588 is a clinical study titled "Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.". In this investigator-initiated study, we will compare changes in brain cognitive biomarkers assessed by diffusion tensor imaging over 2.5 years among 12 patients with Idiopathic Parkinson's disease (IPD) receiving rasagiline, 20 IPD patients not receiving MAO-B inhibitors and 25 age-matched healthy ...
What is the current status of trial NCT02278588?
This trial is currently completed. The enrollment target is 45 participants. The study started on 2014-11. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02278588?
The interventions under investigation include: Rasagiline (DRUG).
Who is sponsoring clinical trial NCT02278588?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.